Intermittent subcutaneous methadone administration in the management of cancer pain

Journal of Pain and Palliative Care Pharmacotherapy

Volumn 19, Issue 2, 2005, Pages 7-12

  Centeno, Carlos ^a   Vara, Francisco ^b  

^a UNIVERSITY CLINIC OF NAVARRA   (Spain)

^b Hospital Los Montalvos   (Spain)

Author keywords

Cancer; Intermittent; Methadone; Pain; Subcutaneous

Indexed keywords

METHADONE; NARCOTIC ANALGESIC AGENT;

ADULT; ADVANCED CANCER; AGED; ARTICLE; BREAST CANCER; CANCER PAIN; CANCER PALLIATIVE THERAPY; CLINICAL ARTICLE; COLON CANCER; DRUG INTERMITTENT THERAPY; DRUG WITHDRAWAL; ERYTHEMA; ESOPHAGUS CANCER; FEMALE; HUMAN; INFLAMMATION; INJECTION SITE REACTION; LUNG CANCER; MALE; MYELOMA; PAIN ASSESSMENT; PANCREAS CANCER; PATIENT COMPLIANCE; RATING SCALE; RECTUM CANCER; STOMACH CANCER;

AGED; AGED, 80 AND OVER; ANALGESICS, OPIOID; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; INJECTIONS, SUBCUTANEOUS; MALE; METHADONE; MIDDLE AGED; NEOPLASMS; PAIN; PALLIATIVE CARE;

EID: 25144439516     PISSN: 15360288     EISSN: None     Source Type: Journal    
DOI: 10.1300/J354v19n02_03     Document Type: Article

References (11)

1. Hanks GW, Conno F, Cherny N. Hanna M, Kalso E, McQuay HJ, Mercadante S, Meynadier J, Poulain P, Ripamonti C, Radbruch L, Casas JR, Sawe J, Twycross RG, Ventafridda V. Morphine and alternative opioids in cancer pain: the EAPC recommendations. Br J Cancer 2001;84:587-93.
2. Walker P, Watanabe S, Lawlor P, Hanson J, Pereira J, Bruera E. Subcutaneous clodronate: a study evaluating efficacy in hypercalcemia of malignancy and local toxicity. Ann Oncol 1997;8:915-6.
3. Sauder C, Porterfield P, Shalansky KF, Tong KL. Subcutaneous administration of loxapine. Am J Health Syst Pharm 1999;56:1259-61.
4. Borner K, Lode H, Hampel B, Pfeuffer M, Koeppe P. Comparative pharmacokinetics of ceftriaxone after subcutaneous and intravenous administration. Chemotherapy 1985;31:237-45.
5. Bruera E, Fainsinger R, Moore M. Thibault R, Spoldi E, Ventafridda V. Local toxicity with subcutaneous methadone. Experience of two centers. Pain 1991;45:141-3.
6. Bohrer: Comment on Bruera et al. Local toxicity with subcutaneous methadone. Experience of two centers. Pain 1991;45:141-143
7. Mathew P, Storey P. Subcutaneous methadone in terminally ill patients: manageable local toxicity. J Pain Symptom Manage. 1999 Jul;18(1):49-52.
8. Makin, MK. Subcutaneous methadone in terminally-ill patients. J Pain Symptom Manage. 2000;19:237-8.
9. Gourlay GK, Cherry DA, Cousins MJ. A comparative study of the efficacy and pharmacokinetics of oral methadone and morphine in the treatment of severe pain in patients with cancer. Pain 1986;25:297-312.
10. Mercadante S, Casuccio A, Fulfaro F, et al. Switching from morphine to methadone to improve analgesia and tolerability in cancer patients: a prospective study. J Clin Oncol 2001;19:2898-904.
11. Ripamonti C, Zecca E, Brunelli, et al. Rectal methadone in cancer patients with pain. A preliminary clinical and pharmacokinetic study. Ann Oncol 1995;6:841-3.